The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
Prostate cancer is the most common non-skin cancer among veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that health care providers screen male veterans for prostate cancer.
ID: NCT05926102
Sponsor; Investigator: VA Office of Research and Development; Jason L. Vassy, MD, MPH
Location: VA Boston Healthcare System
Prostate Active Surveillance Study (PASS)
This research study is for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.
ID: NCT00756665
Sponsor; Collaborators: University of Washington; Canary Foundation, Early Detection Research Network
Locations: VA San Francisco Health Care System, VA Puget Sound Health Care System
A Study of Checkpoint Inhibitors in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP)
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in veterans with metastatic castration-resistant prostate cancer characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to prostate-specific antigen progression, maximal prostate-specific antigen response, time to initiation of alternative antineoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pretreatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
ID: NCT04104893
Sponsor; Collaborator: VA Office of Research and Development; Merck Sharp & Dohme LLC
Locations: San Francisco VAMC, VA Greater Los Angeles Healthcare System, Washington DC VAMC, Bay Pines VA Healthcare System Jesse Brown VAMC, VA Ann Arbor Healthcare System, James J. Peter VAMC, VA NY Harbor Healthcare System, Durham VAMC, Corporal Michael J. Crescenz VAMC, Hunter Holmes McGuire VAMC, VA Puget Sound Health Care System